Matt Gline (L) and Pete Salzmann
Roivant bumps stake in Immunovant with a $200M deal. But with M&A off the table, shares crater
Roivant has worked out a deal to pick up a chunk of stock in its majority-owned sub Immunovant $IMVT, but the stock buy falls far …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
